BRPI0518307A2 - mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 - Google Patents

mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3

Info

Publication number
BRPI0518307A2
BRPI0518307A2 BRPI0518307-3A BRPI0518307A BRPI0518307A2 BR PI0518307 A2 BRPI0518307 A2 BR PI0518307A2 BR PI0518307 A BRPI0518307 A BR PI0518307A BR PI0518307 A2 BRPI0518307 A2 BR PI0518307A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
tlr3 agonist
individual
drug release
Prior art date
Application number
BRPI0518307-3A
Other languages
English (en)
Inventor
Fabrice Andre
Laurence Zitvogel
Jean-Christophe Sabourin
Original Assignee
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave
Publication of BRPI0518307A2 publication Critical patent/BRPI0518307A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO E COMPOSIÇçO DE MATÉRIA PARA TRATAR UM INDIVÍDUO TENDO UM CÂNCER, KIT, COMPOSIÇçO FARMACÊUTICA, MÉTODO PARA IMPREGNAR OU CARREGAR UM DISPOSITIVO IMIPLANTÁVEL DE LIBERAÇçO DE DROGA, DISPOSITIVO IMPLANTÁVEL DE LIBERAÇçO DE DROGA, MÉTODO PARA AVALIAR A RESPOSTA DE UM INDIVÍDUO TENDO CÂNCER A UM TRATAMENTO USANDO UM AGONISTA DE TLR3 OU SELECIONAR UM INDIVÍDUO TENDO UM CÂNCER QUE RESPONDE A UM TRATAMENTO USANDO UM AGONISTA DE TLR3, COMPLEXO, METODO PARA DETERMINAR SE UM COMPOSTO DE TESTE É éTIL PARA O TRATAMENTO DE CÂNCER, E, USO DE UM AGONISTA DE TLR3. A presente invenção refere-se, de uma maneira geral, aos campos da genética e medicina. Mais especificamente, a presente invenção refere-se a métodos melhorados de tratamento de câncer usando um agonisla de TLR3, mediante avaliação da expressão de um receptor TRL3 por células de câncer.
BRPI0518307-3A 2004-11-19 2005-11-18 mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 BRPI0518307A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2004/004093 WO2006054129A1 (en) 2004-11-19 2004-11-19 Improved treatment of cancer by double-stranded rna
US11/144,322 US7378249B2 (en) 2004-11-19 2005-06-03 Treatment of cancer using TLR3 agonists
PCT/IB2005/003641 WO2006054177A1 (en) 2004-11-19 2005-11-18 Improved treatment of cancer using tlr3 agonists

Publications (1)

Publication Number Publication Date
BRPI0518307A2 true BRPI0518307A2 (pt) 2008-11-11

Family

ID=35717497

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518307-3A BRPI0518307A2 (pt) 2004-11-19 2005-11-18 mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3

Country Status (8)

Country Link
US (4) US7378249B2 (pt)
EP (1) EP1812570B1 (pt)
AU (1) AU2005305604B2 (pt)
BR (1) BRPI0518307A2 (pt)
CA (1) CA2587676A1 (pt)
EA (1) EA200701094A1 (pt)
MX (1) MX2007006023A (pt)
WO (2) WO2006054129A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2004087877A2 (en) * 2003-03-26 2004-10-14 Astral Inc. Selected rna motifs to include cell death and/or apoptosis
US20100291118A1 (en) * 2003-12-02 2010-11-18 Innate Pharma Class of Gamma Delta T Cells Activators and Use Thereof
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
CA2605068A1 (en) * 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
WO2007140958A2 (en) 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
EP1881080A1 (en) 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
RU2325920C1 (ru) * 2006-08-29 2008-06-10 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения рака педжета молочной железы
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
WO2008109432A2 (en) * 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
EP2134172A4 (en) * 2007-03-05 2011-06-01 Univ Utah State RESTRICTIVE AGONIST OF THE TOLL LIKE RECEPTOR 3
CA2680060A1 (en) * 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
CA2705859A1 (en) * 2007-10-15 2009-04-23 John P. Stokes Convergent well irradiating plaque for choroidal melanoma
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2009102496A2 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
WO2009126819A1 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
AU2009239655B2 (en) * 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
EP2116602A1 (en) * 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
ES2360334T3 (es) * 2008-06-27 2011-06-03 Theranor Sprl Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
DK2334703T3 (en) * 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
WO2010042229A2 (en) * 2008-10-10 2010-04-15 Hemispherx Biopharma, Inc. Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
AU2009308105B2 (en) * 2008-10-23 2016-07-07 Aim Immunotech Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US9006406B2 (en) * 2008-12-22 2015-04-14 Alexander Levitzki EGFR-homing double-stranded RNA vector for systemic cancer treatment
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
US8217163B2 (en) * 2010-09-20 2012-07-10 Biomics Biotechnologies Co., Ltd. Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
CA2827443C (en) * 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
WO2012131048A1 (en) * 2011-03-31 2012-10-04 Royal College Of Surgeons In Ireland Treatment and prognosis of solid tumour cancers
CN103889453A (zh) * 2011-07-22 2014-06-25 鲍威尔·卡林斯基 肿瘤选择性趋化因子调节
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP2708236A1 (en) * 2012-09-12 2014-03-19 Medizinische Universität Wien Tumor treatment
WO2014165296A1 (en) * 2013-03-12 2014-10-09 Multicell Immunotherapeutics, Inc. Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
KR102589295B1 (ko) 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
US20180117110A1 (en) * 2014-10-03 2018-05-03 The Walter And Eliza Hall Institute Of Medical Research Method of treating cancer
CA2979490C (en) 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3321362A1 (en) * 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
BR112020022294A2 (pt) * 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
CN112703011A (zh) 2018-08-06 2021-04-23 国家医疗保健研究所 用于治疗癌症的方法和组合物
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
EP4048791A4 (en) * 2019-10-22 2024-03-06 AIM ImmunoTech Inc. METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSIS
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
JP2023532717A (ja) 2020-07-02 2023-07-31 ヴィーブ ヘルスケア カンパニー 長期作用型抗レトロウイルス剤を用いたｈｉｖウイルス寛解の達成方法
WO2022189861A1 (en) * 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666646A (en) 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
US5298614A (en) 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
PH24467A (en) * 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ES2331622T3 (es) 1997-05-07 2010-01-11 Schering Corporation Proteinas receptoras humanas similares a toll, reactivos y metodos relacionados.
DE60021354T2 (de) 1999-02-15 2006-04-27 Nippon Shinyaku Co., Ltd. Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
NZ534666A (en) 2000-05-25 2006-01-27 Schering Corp Mammalian DNAX Toll-like receptor protein, DTLR9, antibodies and medicaments made therefrom and use in treating immunological disorders
US20030165479A1 (en) 2001-03-19 2003-09-04 Velleca Mark A. Methods for isolating proteins expressed by dendritic cells
CN1633598A (zh) 2001-10-05 2005-06-29 科勒制药股份公司 Toll样受体3信号传导的激动剂和拮抗剂
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
JP3810731B2 (ja) 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
EP1631687A2 (en) 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands
EP1765361A2 (fr) 2004-06-25 2007-03-28 Institut Gustave Roussy Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
MX2007000770A (es) 2004-07-20 2007-03-26 Schering Corp Induccion de apoptosis en celulas tumorales que expresan el receptor tipo toll.
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna

Also Published As

Publication number Publication date
MX2007006023A (es) 2008-01-14
US7378249B2 (en) 2008-05-27
EA200701094A1 (ru) 2007-12-28
AU2005305604B2 (en) 2011-05-12
US20100266680A1 (en) 2010-10-21
CA2587676A1 (en) 2006-05-26
EP1812570B1 (en) 2012-06-13
EP1812570A1 (en) 2007-08-01
US20080317811A1 (en) 2008-12-25
WO2006054177A1 (en) 2006-05-26
AU2005305604A1 (en) 2006-05-26
US20060110746A1 (en) 2006-05-25
US8409813B2 (en) 2013-04-02
WO2006054129A1 (en) 2006-05-26
US20080253998A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
BRPI0518307A2 (pt) mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3
Henry et al. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo
Gundlah et al. Differences in hypothalamic serotonin between estrous phases and gender: an in vivo microdialysis study
Matsakas et al. Exercise training attenuates the hypermuscular phenotype and restores skeletal muscle function in the myostatin null mouse
Jones et al. Effects of diet and insulin on dopamine transporter activity and expression in rat caudate‐putamen, nucleus accumbens, and midbrain
Bakshi et al. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist
Xapelli et al. Activation of type 1 cannabinoid receptor (CB1R) promotes neurogenesis in murine subventricular zone cell cultures
Hill et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment
Bussey et al. β3‐Adrenoceptor stimulation of perivascular adipocytes leads to increased fat cell‐derived NO and vascular relaxation in small arteries
Tam et al. Signaling mechanisms of melatonin in antiproliferation of hormone‐refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention
Sato et al. Neuronal nitric oxide synthase and gonadal steroid interaction in the MPOA of male rats: co-localization and testosterone-induced restoration of copulation and nNOS-immunoreactivity
Sarantos et al. Pizotifen activates ERK and provides neuroprotection in vitro and in vivo in models of Huntington's disease
Herrold et al. Cellular distribution of AMPA receptor subunits and mGlu5 following acute and repeated administration of morphine or methamphetamine
Zarrindast et al. Effects of dopamine receptor agonist and antagonists on cholestasis-induced anxiolytic-like behaviors in rats
Todd et al. Gabapentin inhibits catecholamine release from adrenal chromaffin cells
Sarantis et al. Exposure to novel environment is characterized by an interaction of D1/NMDA receptors underlined by phosphorylation of the NMDA and AMPA receptor subunits and activation of ERK1/2 signaling, leading to epigenetic changes and gene expression in rat hippocampus
Masini et al. Auditory cortex lesions do not disrupt habituation of HPA axis responses to repeated noise stress
Figueroa et al. ACh‐induced endothelial NO synthase translocation, NO release and vasodilatation in the hamster microcirculation in vivo
Wang et al. GPR37 activation alleviates bone cancer pain via the inhibition of osteoclastogenesis and neuronal hyperexcitability
Rasheed et al. Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats
Ko et al. Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats
Morettini et al. Glucose effectiveness and its components in relation to body mass index
Song et al. The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning
Blais et al. Gastrin-releasing peptide receptor mediates the excitation of preoptic GABAergic neurons by bombesin
Iwata et al. Rabies virus infection prevents the modulation by α2-adrenoceptors, but not muscarinic receptors, of Ca2+ channels in NG108-15 cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE.